ENTRY       D10533            Mixture   Drug
NAME        Umeclidinium bromide and vilanterol;
            Anoro (TN)
PRODUCT     ANORO ELLIPTA (GlaxoSmithKline LLC)
COMPONENT   Umeclidinium bromide [DR:D10181], (Vilanterol trifenatate [DR:D09697] | Vilanterol [DR:D09696])
CLASS       Cardiovascular agent
             DG01456  Adrenergic receptor agonist
              DG01455  beta-Adrenergic receptor agonist
               DG01453  beta3-Adrenergic receptor agonist
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2259
            ATC code: R03AL03
            Product: D10533<JP/US>
EFFICACY    Bronchodilator
  DISEASE   Chronic obstructive pulmonary disease [DS:H01714]
COMMENT     Umeclidinium bromide is primarily metabolized by CYP2D6. 
            Vilanterol trifenatate is primarily metabolized by CYP3A4.
METABOLISM  Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03A ADRENERGICS, INHALANTS
                R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
                 R03AL03 Vilanterol and umeclidinium bromide
                  D10533  Umeclidinium bromide and vilanterol &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Bronchodilator Combinations
               Umeclidinium/ Vilanterol
                D10533  Umeclidinium bromide and vilanterol
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               225  Bronchodilators
                2259  Others
                 D10533  Umeclidinium bromide and vilanterol
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01456  Adrenergic receptor agonist
               DG01455  beta-Adrenergic receptor agonist
                DG01453  beta3-Adrenergic receptor agonist
                 D10533  Umeclidinium bromide and vilanterol
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               D10533  Umeclidinium bromide and vilanterol
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10533  Umeclidinium bromide and vilanterol
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10533
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10533
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10533
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10533
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10533
DBLINKS     PubChem: 254741495
///
